Sarepta Therapeutics Inc (SRPT)
117.83
+0.54
(+0.46%)
USD |
NASDAQ |
Apr 17, 16:00
118.00
+0.17
(+0.14%)
After-Hours: 05:44
Sarepta Therapeutics Gross Profit Margin (Quarterly): 88.87% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 88.87% |
September 30, 2023 | 88.84% |
June 30, 2023 | 86.94% |
March 31, 2023 | 86.19% |
December 31, 2022 | 88.08% |
September 30, 2022 | 82.65% |
June 30, 2022 | 83.81% |
March 31, 2022 | 85.09% |
December 31, 2021 | 84.24% |
September 30, 2021 | 87.62% |
June 30, 2021 | 88.11% |
March 31, 2021 | 84.79% |
December 31, 2020 | 84.56% |
September 30, 2020 | 89.57% |
June 30, 2020 | 90.29% |
Date | Value |
---|---|
March 31, 2020 | 88.90% |
December 31, 2019 | 84.45% |
September 30, 2019 | 86.84% |
June 30, 2019 | 83.18% |
March 31, 2019 | 86.14% |
December 31, 2018 | 84.44% |
September 30, 2018 | 88.86% |
June 30, 2018 | 90.84% |
March 31, 2018 | 91.36% |
December 31, 2017 | 93.81% |
September 30, 2017 | 93.30% |
June 30, 2017 | 98.55% |
March 31, 2017 | 98.64% |
December 31, 2016 | 98.14% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
82.65%
Minimum
Sep 2022
90.29%
Maximum
Jun 2020
86.47%
Average
86.84%
Median
Sep 2019
Gross Profit Margin (Quarterly) Benchmarks
CytomX Therapeutics Inc | -- |
PTC Therapeutics Inc | 90.52% |
Vertex Pharmaceuticals Inc | 85.38% |
Puma Biotechnology Inc | 66.30% |
Regenxbio Inc | 49.41% |
Gross Profit Margin (Quarterly) Related Metrics
Return on Equity | -77.39% |
Return on Assets | -17.08% |
Return on Invested Capital | -26.93% |
Profit Margin (Quarterly) | 11.51% |
Operating Margin (Quarterly) | 6.21% |
Return on Net Operating Assets | -54.08% |